CELx
This article was originally published in The Gray Sheet
Executive Summary
IMRE diagnostic subsidiary gains exclusive worldwide license from Virginia Mason Research Center for a rheumatoid arthritis genetic test. CELx plans to seek 510(k) clearance for the test, which it hopes to receive within 18 months. Intended for patients who have already been diagnosed with rheumatoid arthritis, the test would identify those who exhibit a high probability of developing more severe symptoms, thus permitting early treatmen